MA47408B1 - Traitement du cancer - Google Patents

Traitement du cancer

Info

Publication number
MA47408B1
MA47408B1 MA47408A MA47408A MA47408B1 MA 47408 B1 MA47408 B1 MA 47408B1 MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A MA 47408 B1 MA47408 B1 MA 47408B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
erdafitinib
relates
present
treating cancer
Prior art date
Application number
MA47408A
Other languages
English (en)
Other versions
MA47408A (fr
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/fr
Publication of MA47408B1 publication Critical patent/MA47408B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention concerne un procédé de traitement du cancer par l'erdafitinib
MA47408A 2017-12-20 2018-02-02 Traitement du cancer MA47408B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (fr) 2017-02-06 2018-02-02 Traitement du cancer

Publications (2)

Publication Number Publication Date
MA47408A MA47408A (fr) 2019-12-11
MA47408B1 true MA47408B1 (fr) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (fr) 2017-12-20 2018-02-02 Traitement du cancer

Country Status (5)

Country Link
EA (1) EA201991818A1 (fr)
MA (1) MA47408B1 (fr)
PT (1) PT3576740T (fr)
TW (1) TWI798199B (fr)
WO (1) WO2018141921A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53655A (fr) * 2018-09-21 2021-12-29 Janssen Pharmaceutica Nv Traitement du cholangiocarcinome
EP3898615A1 (fr) * 2018-12-19 2021-10-27 Array Biopharma, Inc. Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer
AU2020223467A1 (en) * 2019-02-12 2021-08-05 Janssen Pharmaceutica Nv Cancer treatment
CA3133348A1 (fr) * 2019-03-15 2020-09-24 Poly-Med, Inc. Systemes d'administration, methodes et compositions formant un gel in situ
MX2021011943A (es) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CN114207151A (zh) * 2019-05-31 2022-03-18 Qed医药股份有限公司 治疗泌尿***癌症的方法
US20230011935A1 (en) * 2019-12-09 2023-01-12 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
IL295514A (en) * 2020-02-12 2022-10-01 Janssen Pharmaceutica Nv fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle-invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Also Published As

Publication number Publication date
MA47408A (fr) 2019-12-11
WO2018141921A1 (fr) 2018-08-09
PT3576740T (pt) 2023-08-18
EA201991818A1 (ru) 2020-02-05
TW201839399A (zh) 2018-11-01
TWI798199B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
MA47408B1 (fr) Traitement du cancer
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
NZ728636A (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MA53329A (fr) Méthodes de traitement de l'épilepsie
SG10201900564WA (en) Methods for treating cancer
EA201792610A1 (ru) Способ лечения неврологического заболевания
MA51525A (fr) Traitement de minéraux
MA55209A (fr) Procédés de traitement de l'amylose al
MA54559A (fr) Polythérapie pour le traitement du cancer
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MA56033A (fr) Méthodes de traitement de la sclérodermie généralisée
MA54465A (fr) Inhibiteurs de cxcr7 destinés au traitement du cancer
BR112017020408A2 (pt) ?biotinas e composições?